Multicomponent solids of lamotrigine with some selected coformers and their characterization by thermoanalytical, spectroscopic and X-ray diffraction methods

The present study investigates the structural and pharmaceutical properties of different multicomponent crystalline forms of lamotrigine (LTG) with some pharmaceutically acceptable coformers viz.nicotinamide (1), acetamide (2), acetic acid (3), 4-hydroxy-benzoic acid (4) and saccharin (5). The structurally homogeneous phases were characterized in the solid state by DSC/TGA, FT-IR and XRD (powder and single crystal structure analysis) as well as in the solution phase. Forms 1 and 2 were found to be cocrystal hydrate and cocrystal, respectively, while in forms 3, 4 and 5, proton transfer was observed from coformer to drug. The enthalpy of formation of multicomponent crystals from their components was determined from the enthalpy of solution of the cocrystals and the components separately. Higher exothermic values of the enthalpy of formation for molecular complexes 3, 4 and 5 suggest these to be more stable than 1 and 2. The solubility was measured in water as well as in phosphate buffers of varying pH. The salt solvate 3 exhibited the highest solubility of the drug in water as well as in buffers over the pH range 7–3 while the cocrystal hydrate 1 showed the maximum solubility in a buffer of pH 2. A significant lowering of the dosage profile of LTG was observed for 1, 3 and 5 in the animal activity studies on mice.

[1]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[2]  K. Amighi,et al.  Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. , 2005, International journal of pharmaceutics.

[3]  Balasubramanian Sridhar,et al.  Lamotrigine, an antiepileptic drug, and its chloride and nitrate salts. , 2009, Acta crystallographica. Section C, Crystal structure communications.

[4]  Christer B Aakeröy,et al.  Cocrystal or salt: does it really matter? , 2007, Molecular pharmaceutics.

[5]  Yasuo Ida,et al.  Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  B. Sridhar,et al.  Lamotriginium benzoate dimethyl­formamide solvate , 2005 .

[7]  Elies Molins,et al.  Effect of the Counterion on the Solubility of Isostructural Pharmaceutical Lamotrigine Salts , 2009 .

[8]  A. Adjei,et al.  Extended Hildebrand solubility approach: solubility of theophylline in polar binary solvents. , 1980, Journal of pharmaceutical sciences.

[9]  Gautam R. Desiraju,et al.  Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities , 2005 .

[10]  S. Rohani,et al.  Preparation and Characterization of Theophylline-Nicotinamide Cocrystal , 2009 .

[11]  Andrew V. Trask,et al.  An overview of pharmaceutical cocrystals as intellectual property. , 2007, Molecular pharmaceutics.

[12]  Anthony L. Spek,et al.  Journal of , 1993 .

[13]  Louis J. Farrugia,et al.  ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI) , 1997 .

[14]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[15]  B. Roth,et al.  Pharmacological Studies on Lamotrigine, A Novel Potential Antiepileptic Drug , 1986, Epilepsia.

[16]  N. Sheth,et al.  Inclusion complexes of lamotrigine and hydroxy propyl β-cyclodextrin: solid state characterization and dissolution studies , 2009 .

[17]  Aeri Park,et al.  The salt-cocrystal continuum: the influence of crystal structure on ionization state. , 2007, Molecular pharmaceutics.

[18]  Miranda L. Cheney,et al.  Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine , 2010 .

[19]  Donald C. Monkhouse,et al.  Review ArticlePharmaceutical Salts , 1977 .

[20]  M. Leach,et al.  X-ray Crystallographic Structures of Neuroprotective Pyrimidine Derivatives: (I) the Mesylate Salt of BW1003C87 and (II) Sipatrigine Base , 2007 .

[21]  R. W. Janes.  Crystal structure of an analog of the anticonvulsant lamotrigine, 3,5-diamino-6-(2,3,5-trichlorophenyl)-1,2,4-triazine·dimethanolate, and structure comparisons with related analogs , 1999 .

[22]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[23]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[24]  W. Tong,et al.  In situ salt screening--a useful technique for discovery support and preformulation studies. , 1998, Pharmaceutical development and technology.

[25]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[26]  A. Newman,et al.  Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.

[27]  Sekhar Surapaneni,et al.  The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.

[28]  A. Bak,et al.  Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals , 2008 .

[29]  T. N. Guru Row,et al.  Nature of Cl···Cl intermolecular interactions via experimental and theoretical charge density analysis: correlation of polar flattening effects with geometry. , 2010, The journal of physical chemistry. A.

[30]  W. Curatolo,et al.  Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.

[31]  Abu T M Serajuddin,et al.  Salt formation to improve drug solubility. , 2007, Advanced drug delivery reviews.

[32]  Yoshiki Hayashi,et al.  Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-soluble Compounds , 2008, Pharmaceutical Research.

[33]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[34]  C. Macrae,et al.  Mercury CSD 2.0 – new features for the visualization and investigation of crystal structures , 2008 .

[35]  S. Velaga,et al.  Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization , 2008, Pharmaceutical Research.

[36]  B. Sridhar,et al.  Crystal Structure of Lamotriginium Hydrogen Phthalate Dimethylformamide Solvate (1:1:1) , 2006 .

[37]  R. W. Janes,et al.  Structure of lamotrigine methanol solvate: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine–methanol, a novel anticonvulsant drug , 1989 .

[38]  B. Sridhar,et al.  Lamotrigine dimethyl­formamide sesquisolvate , 2006 .

[39]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  Sharmistha Datta,et al.  Crystal structures of drugs: advances in determination, prediction and engineering , 2004, Nature reviews. Drug discovery.

[41]  Jeanette T. Dunlap,et al.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.

[42]  M. Leach,et al.  Structure of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate solvate (lamotrigine isethionate) , 1999 .

[43]  Naír Rodríguez-Hornedo,et al.  Solubility Advantage of Pharmaceutical Cocrystals , 2009 .

[44]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[45]  K. Mäder,et al.  Preparation and characterization of a self-emulsifying pellet formulation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[46]  P. W. Codding,et al.  Hydrogen bonding patterns in 3,5-diamino-6-aryl triazines , 2001 .